Category: Press Release

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 20, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel. A live webcast of the presentation can be accessed by visiting

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 15, 2018– AVEO Oncology (NASDAQ: AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the commercial launch and reimbursement in Germany of FOTIVDA® (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma (RCC). In the European Union, Norway and Iceland, tivozanib is indicated for the first line

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 9, 2018– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2018 and provided a business update. “The recent announcement of positive topline results from the Phase 3 TIVO-3 study in renal cell carcinoma is transformative for AVEO, and the next step of an ongoing, multi-year effort to ensure tivozanib (FOTIVDA®)

Download PDF – First and Only Positive Phase 3 Study in Third- and Fourth-Line RCC – – Primary Endpoint Shows 44% Improvement in Median PFS and 26% Reduction in Risk of Progression or Death (HR=0.74, p=0.02) for Tivozanib Compared to Sorafenib – – Data for Secondary Endpoint of Overall Survival Not Yet Mature;Final Analysis Planned

Download PDF Tivozanib-Nivolumab Combination Continues to Demonstrate Favorable Efficacy and Safety Data Presented at the European Society of Medical Oncology (ESMO) 2018 Annual Congress CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Oct. 22, 2018– AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of updated interim results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 9, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that updated interim data from the Phase 2 portion of the TiNivo trial of tivozanib and nivolumab (OPDIVO®) in advanced renal cell carcinoma will be presented at the European Society of Medical Oncology (ESMO) 2018 Annual Congress being held October 19-23, 2018 in Munich, Germany. The TiNivo study is a

Download PDF – Analysis Initiated on the Unanimous Recommendation of the TIVO-3 Study Independent Steering Committee – – Company Expects to Report Topline Results in Approximately 6 Weeks – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 1, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated topline analysis of the phase 3 TIVO-3 clinical trial on the unanimous recommendation of the independent TIVO-3

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 25, 2018– AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 28, 2018– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer, will participate in the following investor conferences: A live webcast of Mr. Bailey’s presentation at the Rodman & Renshaw conference can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 17, 2018– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that it has priced an underwritten public offering of 2,500,000 shares of common stock at a price to the public of $2.26 per share, the closing price as of yesterday, August 16, 2018, which would result in aggregate gross proceeds of approximately $5.7 million before underwriting discounts. All of